Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015
Research

Hospitalization Frequency and Charges for Neurocysticercosis, United States, 2003–2012

Seth E. O’NealComments to Author  and Robert H. Flecker
Author affiliations: Oregon Health & Science University, Portland, Oregon, USA

Main Article

Table 1

Supporting diagnostic or procedural codes from ICD-9-CM used for conservative case definition for reporting hospitalizations associated with neurocysticercosis*

CCS code Diagnosis or procedure
Diagnostic code
76 Meningitis
77 Encephalitis
78 Other CNS infection and poliomyelitis
83 Epilepsy; convulsions
84 Headache; including migraine
85 Coma; stupor; and brain damage
90 Inflammation; infection of eye
95 Other nervous system disorders
109 Acute cerebrovascular disease
111 Other and ill-defined cerebrovascular disease
112 Transient cerebral ischemia
245 Syncope
650 Adjustment disorders
651 Anxiety disorders
652 Attention-deficit, conduct, and disruptive behavior disorders
653 Delirium, dementia, and amnestic and other cognitive disorders
656 Impulse control disorders, NEC
657 Mood disorders
658 Personality disorders
659 Schizophrenia and other psychotic disorders
662 Suicide and intentional self-inflicted injury
670 Miscellaneous mental disorders
Procedural codes
1 Incision and excision of CNS
2 Insertion; replacement; or removal of extracranial ventricular shunt
177 Computerized axial tomography (CT) scan head
198 Magnetic resonance imaging
199 Electroencephalogram (EEG)

*A complete list of ICD-9-CM codes used in this study is provided in the online Technical Appendix (http://wwwnc.cdc.gov/EID/article/21/6/14-1324-Techapp1.pdf). ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; CCS, Clinical Classification Software groupings of ICD-9-CM codes (12); CNS, central nervous system; NEC, not elsewhere classified.

Main Article

References
  1. Ndimubanzi  PC, Carabin  H, Budke  CM, Nguyen  H, Qian  Y-J, Rainwater  E, A systematic review of the frequency of neurocysticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis. 2010;4:e870. DOIPubMedGoogle Scholar
  2. Coyle  CM, Mahanty  S, Zunt  JR, Wallin  MT, Cantey  PT, White  AC Jr, Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis. 2012;6:e1500. DOIPubMedGoogle Scholar
  3. Scharf  D. Neurocysticercosis. Two hundred thirty-eight cases from a California hospital. Arch Neurol. 1988;45:777–80. DOIPubMedGoogle Scholar
  4. Shandera  WX, White  AC, Chen  JC, Diaz  P, Armstrong  R. Neurocysticercosis in Houston, Texas. A report of 112 cases. Medicine (Baltimore). 1994;73:37–52. DOIPubMedGoogle Scholar
  5. Wallin  MT, Kurtzke  JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. 2004;63:1559–64. DOIPubMedGoogle Scholar
  6. Crompton DWT, editor. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases. Geneva: World Health Organization; 2013.
  7. World Health Organization. 66th Assembly. “Resolution WHA66.12” May 2013. Neglected tropical diseases [cited 2015 Apr 9]. http://www.who.int/neglected_diseases/mediacentre/WHA_66.12_Eng.pdf
  8. World Organisation for Animal Health, World Health Organization, Food and Agriculture Organization. WHO/FAO/OIE guidelines for the surveillance, prevention and control of taeniosis/cysticercosis [cited 2015 Apr 9]. http://www.oie.int/doc/ged/d11245.pdf
  9. Sorvillo  FJ, DeGiorgio  C, Waterman  SH. Deaths from cysticercosis, United States. Emerg Infect Dis. 2007;13:230–5. DOIPubMedGoogle Scholar
  10. Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project. Introduction to the HCUP Nationwide Inpatient Sample (NIS), 2011. Rockville (MD): The Agency; 2013 [cited 2015 Jan 6]. http://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2011.pdf
  11. Steiner  C, Elixhauser  A, Schnaier  J. The healthcare cost and utilization project: an overview. Eff Clin Pract. 2002;5:143–51.PubMedGoogle Scholar
  12. O’Neal  S, Noh  J, Wilkins  P, Keene  W, Andersen  J, Lambert  W, Surveillance and screening for Taenia solium infection, Oregon, USA. Emerg Infect Dis. 2011;17:1030–6.PubMedGoogle Scholar
  13. Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project. Clinical Classifications Software (CCS) for ICD-9-CM [cited 2014 May 2]. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
  14. Centers for Disease Control and Prevention. Buruli ulcer: technical information [cited 2015 Apr 9]. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/buruliulcer_t.htm
  15. Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project. Population denominator data for use with the HCUP databases, 2003–2012 data [cited 2014 Nov 2]. http://www.hcup-us.ahrq.gov/reports/methods/2013_01_AppendixA.zip
  16. Townes  JM, Hoffmann  CJ, Kohn  MA. Neurocysticercosis in Oregon, 1995–2000. Emerg Infect Dis. 2004;10:508–10. DOIPubMedGoogle Scholar
  17. Ehnert  KL, Roberto  RR, Barrett  L, Sorvillo  FJ, Rutherford  GW III. Cysticercosis: first 12 months of reporting in California. Bull Pan Am Health Organ. 1992;26:165–72.PubMedGoogle Scholar
  18. Croker  C, Redelings  M, Reporter  R, Sorvillo  F, Mascola  L, Wilkins  P. The impact of neurocysticercosis in California: a review of hospitalized cases. PLoS Negl Trop Dis. 2012;6:e1480. DOIPubMedGoogle Scholar
  19. Sorvillo  FJ, Waterman  SH, Richards  FO, Schantz  PM. Cysticercosis surveillance: locally acquired and travel-related infections and detection of intestinal tapeworm carriers in Los Angeles County. Am J Trop Med Hyg. 1992;47:365–71.PubMedGoogle Scholar
  20. Croker  C, Reporter  R, Mascola  L. Use of statewide hospital discharge data to evaluate the economic burden of neurocysticercosis in Los Angeles County (1991–2008). Am J Trop Med Hyg. 2010;83:106–10. DOIPubMedGoogle Scholar
  21. US Census Bureau. 2012 national population projections [cited 2014 Apr 28] http://www.census.gov/population/projections/data/national/2012.html
  22. Serpa  JA, Graviss  EA, Kass  JS, White  AC Jr. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore). 2011;90:81–6. DOIPubMedGoogle Scholar
  23. Cuetter  AC, Andrews  RJ. Intraventricular neurocysticercosis: 18 consecutive patients and review of the literature. Neurosurg Focus. 2002;12:e5. DOIPubMedGoogle Scholar
  24. García  HH, Evans  CA, Nash  TE, Takayanagui  OM, White  AC Jr, Botero  D, Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15:747–56. DOIPubMedGoogle Scholar
  25. Sotelo  J, Marin  C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg. 1987;66:686–9. DOIPubMedGoogle Scholar
  26. Kelley  R, Duong  DH, Locke  GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery. 2002;50:757–61. DOIPubMedGoogle Scholar
  27. Nash  TE, Mahanty  S, Garcia  HH; Cysticercosis Group in Peru. Corticosteroid use in neurocysticercosis. Expert Rev Neurother. 2011;11:1175–83. DOIPubMedGoogle Scholar
  28. del la Garza  Y, Graviss  EA, Daver  NG, Gambarin  KJ, Shandera  WX, Schantz  PM, Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg. 2005;73:766–70.PubMedGoogle Scholar

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external